Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara

Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to ...

Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.

Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.

Don't sleep on these medical device leaders.

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.

The Schwab U.S. Dividend Equity ETF is anything but boring.

Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for investors weighing portfolio strategy.

All three ETFs complement each other well in a portfolio.

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

Abbott Labs could rally in a downturn and has a long-term growth catalyst to boot.

These healthcare stocks may be the building blocks of a winning portfolio.

July earnings matter, but long-term growth matters more.

Now's the time to load up on these high-yielders.

Analysts remain relatively more upbeat, but this could prove fleeting.

Visa, Home Depot, and Abbott Laboratories are blue chip stocks that can provide your portfolio with a good mix of safety, stability, and dividend income over the long term.

Declining sales of plant-based meats have the company looking for other revenue sources.

Grail is on a quest to win in a $50 billion market.

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

This particular sector may suit cautious and aggressive investors.